A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (NCT05083169)

🧪 Interventions in This Study

• Daratumumab (DRUG)
• Pomalidomide (DRUG)
• Dexamethasone (DRUG)
• Bortezomib (DRUG)
• Teclistamab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (176 Sites)

Showing the first 25 of 176 sites.

• University of Alabama Birmingham — Birmingham, Alabama
• City of Hope — Duarte, California
• Stanford University Medical Center — Stanford, California
• Yale University — New Haven, Connecticut
• Emory University Winship Cancer Institute — Atlanta, Georgia
• Tufts Medical Center — Boston, Massachusetts
• Henry Ford Hospital — Detroit, Michigan
• Henry Ford Health System — Southfield, Michigan
• Cleveland Clinic — Cleveland, Ohio
• West Penn Hospital — Pittsburgh, Pennsylvania
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
• Medical University of South Carolina — Charleston, South Carolina
• Baptist Cancer Center — Memphis, Tennessee
• Vanderbilt Ingram Cancer Center — Nashville, Tennessee
• University of Texas Southwestern Medical Center — Dallas, Texas
• Huntsman Cancer Institute — Salt Lake City, Utah
• Fred Hutchinson Cancer Center — Seattle, Washington
• University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
• Hospital Italiano de Buenos Aires — Buenos Aires,
• Hospital Aleman — CABA,
• Hospital Privado Centro Medico de Cordoba — Córdoba,
• ZAS Cadix — Antwerp,
• AZ St.-Jan Brugge-Oostende AV — Bruges,
• UZ Gent — Ghent,
• Hopital de Jolimont — Haine Saint Paul La Louviere,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.